# Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)

> **NCT03909724** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Cancer
- Metastasis

## Interventions

- **DRUG:** Sunitinib Malate
- **DRUG:** TAS 102

## Key facts

- **NCT ID:** NCT03909724
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2021-07-01
- **Final completion:** 2022-07-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03909724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03909724, "Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03909724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*